immunology, HIV, infectious disease

Umbilical cord blood may be a good alternative to bone marrow transplants for treating HIV in patients with HIV and cancer.

Those with two copies of the Δ32 allele in the CCR5 gene are 21 percent more likely to die by age 76, although it’s not clear why.

Some patients could suppress the virus without antiretroviral therapy for months after the drug infusions.

The receptors, found in so-called elite controllers who don’t need medications to keep the virus in check, suggest a new path toward immunotherapy.

Another case of HIV remission emerges, this time in a South African girl diagnosed as an infant and disease-free for more than eight years.

Engineered immunogens based on conserved patches of the virus’s envelope protein point to new strategies for vaccine design.

From diagnostics to vaccines, llama antibodies point to new directions in HIV research.

An immune protein previously thought to mark inactive T cells has a free-floating form that correlates with HIV disease progression.

Recent discoveries are spurring a renaissance in HIV vaccine research and development.

Alan Aderem earned his PhD while under house arrest for protesting apartheid in South Africa. His early political involvement has guided his scientific focus, encouraging fellow systems biologists to study immunology and infectious diseases.

With much of his early career dictated by US Navy interests, Carl June drew inspiration from malaria, bone marrow transplantation, and HIV in his roundabout path to a breakthrough in cancer immunotherapy.

Editor accused of fraud leaves post; the good and the bad of gut microbiota; bacterial gene shuffle; legal restrictions hamper illicit drug research; antibodies and autism

New molecular analyses yield clues to the success of a 2009 human HIV vaccine study.

By a fortuitous twist of genetic fate, a small percentage of humans, roughly one in 100, are able to resist infection to HIV.